Cargando…

Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects

Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone inju...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Jose R., Kouroupis, Dimitrios, Li, Deborah J., Best, Thomas M., Kaplan, Lee, Correa, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079270/
https://www.ncbi.nlm.nih.gov/pubmed/30109228
http://dx.doi.org/10.3389/fbioe.2018.00105
_version_ 1783345237693825024
author Perez, Jose R.
Kouroupis, Dimitrios
Li, Deborah J.
Best, Thomas M.
Kaplan, Lee
Correa, Diego
author_facet Perez, Jose R.
Kouroupis, Dimitrios
Li, Deborah J.
Best, Thomas M.
Kaplan, Lee
Correa, Diego
author_sort Perez, Jose R.
collection PubMed
description Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis—AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration.
format Online
Article
Text
id pubmed-6079270
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60792702018-08-14 Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects Perez, Jose R. Kouroupis, Dimitrios Li, Deborah J. Best, Thomas M. Kaplan, Lee Correa, Diego Front Bioeng Biotechnol Bioengineering and Biotechnology Bone fractures and segmental bone defects are a significant source of patient morbidity and place a staggering economic burden on the healthcare system. The annual cost of treating bone defects in the US has been estimated to be $5 billion, while enormous costs are spent on bone grafts for bone injuries, tumors, and other pathologies associated with defective fracture healing. Autologous bone grafts represent the gold standard for the treatment of bone defects. However, they are associated with variable clinical outcomes, postsurgical morbidity, especially at the donor site, and increased surgical costs. In an effort to circumvent these limitations, tissue engineering and cell-based therapies have been proposed as alternatives to induce and promote bone repair. This review focuses on the recent advances in bone tissue engineering (BTE), specifically looking at its role in treating delayed fracture healing (non-unions) and the resulting segmental bone defects. Herein we discuss: (1) the processes of endochondral and intramembranous bone formation; (2) the role of stem cells, looking specifically at mesenchymal (MSC), embryonic (ESC), and induced pluripotent (iPSC) stem cells as viable building blocks to engineer bone implants; (3) the biomaterials used to direct tissue growth, with a focus on ceramic, biodegradable polymers, and composite materials; (4) the growth factors and molecular signals used to induce differentiation of stem cells into the osteoblastic lineage, which ultimately leads to active bone formation; and (5) the mechanical stimulation protocols used to maintain the integrity of the bone repair and their role in successful cell engraftment. Finally, a couple clinical scenarios are presented (non-unions and avascular necrosis—AVN), to illustrate how novel cell-based therapy approaches can be used. A thorough understanding of tissue engineering and cell-based therapies may allow for better incorporation of these potential therapeutic approaches in bone defects allowing for proper bone repair and regeneration. Frontiers Media S.A. 2018-07-31 /pmc/articles/PMC6079270/ /pubmed/30109228 http://dx.doi.org/10.3389/fbioe.2018.00105 Text en Copyright © 2018 Perez, Kouroupis, Li, Best, Kaplan and Correa. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Perez, Jose R.
Kouroupis, Dimitrios
Li, Deborah J.
Best, Thomas M.
Kaplan, Lee
Correa, Diego
Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title_full Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title_fullStr Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title_full_unstemmed Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title_short Tissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
title_sort tissue engineering and cell-based therapies for fractures and bone defects
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079270/
https://www.ncbi.nlm.nih.gov/pubmed/30109228
http://dx.doi.org/10.3389/fbioe.2018.00105
work_keys_str_mv AT perezjoser tissueengineeringandcellbasedtherapiesforfracturesandbonedefects
AT kouroupisdimitrios tissueengineeringandcellbasedtherapiesforfracturesandbonedefects
AT lideborahj tissueengineeringandcellbasedtherapiesforfracturesandbonedefects
AT bestthomasm tissueengineeringandcellbasedtherapiesforfracturesandbonedefects
AT kaplanlee tissueengineeringandcellbasedtherapiesforfracturesandbonedefects
AT correadiego tissueengineeringandcellbasedtherapiesforfracturesandbonedefects